Peter McWilliams

Peter McWilliams is a Venture Partner with Sanderling Ventures and has more than 15 years of experience in biomedical research and management. He works actively with Sanderling portfolio companies in the role of Chairman, Director, CEO, and member of the management team. Prior to Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin. Prior to that, he was an Associate with Booz & Co. (now PwC) in San Francisco where he focused on projects for major US and International life science companies. Prior to that, he was a Software Engineer and Applications Specialist with Oxford Molecular.

Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.